Stay updated on BNT162b2 Vaccine Lots & Doses in Healthy Participants Clinical Trial

Sign up to get notified when there's something new on the BNT162b2 Vaccine Lots & Doses in Healthy Participants Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BNT162b2 Vaccine Lots & Doses in Healthy Participants Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the dose level of the SARS-CoV-2 RNA vaccine candidate (BNT162b2) from 30-microgram to 20-microgram, administered from one of the manufacturing lots in a Phase 3 study for healthy participants aged 12 through 50 years.
    Difference
    0.1%
    Check dated 2024-06-06T14:39:09.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria,' providing examples such as general health condition or prior treatments. Additionally, detailed inclusion and exclusion criteria for the primary and booster studies have been specified.
    Difference
    29%
    Check dated 2024-05-22T21:10:06.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:39:17.000Z thumbnail image

Stay in the know with updates to BNT162b2 Vaccine Lots & Doses in Healthy Participants Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BNT162b2 Vaccine Lots & Doses in Healthy Participants Clinical Trial page.